Italian biomedical charity Fondazione Telethon, which is focused on rare genetic diseases, revealed it has submitted a Biologics License Application (BLA) for the gene therapy - etuvetidigene autotemcel – as a treatment of patients with Wiskott-Aldrich syndrome (WAS), a rare genetic disease of the immune system, to the US Food and Drug Administration (FDA).
The announcement follows closely on the heels of the submission of the marketing authorization request to the European Medicine Agency (EMA). After positioning itself as the first charity in the world to assume responsibility for the production and distribution of a drug – the gene therapy for the treatment of adenosine deaminase (ADA-SCID)], these submissions for another advanced therapeutic medicinal product to both agencies confirm the Foundation's commitment to managing the production and distribution of medicinal products when they would not otherwise be made available by the pharmaceutical industry.
As the treatment for ADA-SCID, also etuvetidigene autotemcel gene therapy originated from research carried out by the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGER, Milan), a leader in the field of advanced therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze